nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—CYP2B6—Methimazole—Graves' disease	0.259	0.405	CbGbCtD
Regorafenib—CYP2C19—Methimazole—Graves' disease	0.164	0.257	CbGbCtD
Regorafenib—CYP2C9—Methimazole—Graves' disease	0.137	0.214	CbGbCtD
Regorafenib—CYP3A4—Methimazole—Graves' disease	0.0794	0.124	CbGbCtD
Regorafenib—Traumatic liver injury—Propylthiouracil—Graves' disease	0.0161	0.256	CcSEcCtD
Regorafenib—DDR2—eye—Graves' disease	0.00727	0.0353	CbGeAlD
Regorafenib—Liver injury—Propylthiouracil—Graves' disease	0.00713	0.113	CcSEcCtD
Regorafenib—DDR2—connective tissue—Graves' disease	0.00701	0.034	CbGeAlD
Regorafenib—DDR2—pituitary gland—Graves' disease	0.0054	0.0262	CbGeAlD
Regorafenib—DDR2—adipose tissue—Graves' disease	0.00538	0.0261	CbGeAlD
Regorafenib—MAPK11—adipose tissue—Graves' disease	0.0051	0.0247	CbGeAlD
Regorafenib—EPHX2—eye—Graves' disease	0.00491	0.0238	CbGeAlD
Regorafenib—DDR2—thyroid gland—Graves' disease	0.00465	0.0226	CbGeAlD
Regorafenib—FLT4—eye—Graves' disease	0.00443	0.0215	CbGeAlD
Regorafenib—MAPK11—thyroid gland—Graves' disease	0.00441	0.0214	CbGeAlD
Regorafenib—BRAF—pituitary gland—Graves' disease	0.00382	0.0185	CbGeAlD
Regorafenib—BRAF—adipose tissue—Graves' disease	0.0038	0.0184	CbGeAlD
Regorafenib—RET—connective tissue—Graves' disease	0.00377	0.0183	CbGeAlD
Regorafenib—FGFR2—eye—Graves' disease	0.00372	0.018	CbGeAlD
Regorafenib—EPHX2—pituitary gland—Graves' disease	0.00365	0.0177	CbGeAlD
Regorafenib—EPHX2—adipose tissue—Graves' disease	0.00363	0.0176	CbGeAlD
Regorafenib—FGFR2—connective tissue—Graves' disease	0.00358	0.0174	CbGeAlD
Regorafenib—FLT1—eye—Graves' disease	0.00345	0.0167	CbGeAlD
Regorafenib—TEK—connective tissue—Graves' disease	0.00343	0.0167	CbGeAlD
Regorafenib—RAF1—eye—Graves' disease	0.00343	0.0166	CbGeAlD
Regorafenib—FLT1—connective tissue—Graves' disease	0.00332	0.0161	CbGeAlD
Regorafenib—RAF1—connective tissue—Graves' disease	0.0033	0.016	CbGeAlD
Regorafenib—BRAF—thyroid gland—Graves' disease	0.00329	0.016	CbGeAlD
Regorafenib—FLT4—adipose tissue—Graves' disease	0.00328	0.0159	CbGeAlD
Regorafenib—FGFR1—pituitary gland—Graves' disease	0.00324	0.0157	CbGeAlD
Regorafenib—FGFR1—adipose tissue—Graves' disease	0.00323	0.0157	CbGeAlD
Regorafenib—EPHX2—thyroid gland—Graves' disease	0.00314	0.0153	CbGeAlD
Regorafenib—Alopecia—Methimazole—Graves' disease	0.00313	0.0498	CcSEcCtD
Regorafenib—PDGFRA—connective tissue—Graves' disease	0.00311	0.0151	CbGeAlD
Regorafenib—Haemoglobin—Propylthiouracil—Graves' disease	0.00303	0.0481	CcSEcCtD
Regorafenib—Haemorrhage—Propylthiouracil—Graves' disease	0.00301	0.0479	CcSEcCtD
Regorafenib—KDR—eye—Graves' disease	0.00291	0.0141	CbGeAlD
Regorafenib—RET—pituitary gland—Graves' disease	0.0029	0.0141	CbGeAlD
Regorafenib—FLT4—thyroid gland—Graves' disease	0.00284	0.0138	CbGeAlD
Regorafenib—KDR—connective tissue—Graves' disease	0.00281	0.0136	CbGeAlD
Regorafenib—FGFR1—thyroid gland—Graves' disease	0.0028	0.0136	CbGeAlD
Regorafenib—Leukopenia—Methimazole—Graves' disease	0.00276	0.0439	CcSEcCtD
Regorafenib—FGFR2—adipose tissue—Graves' disease	0.00275	0.0133	CbGeAlD
Regorafenib—EPHA2—pituitary gland—Graves' disease	0.00271	0.0132	CbGeAlD
Regorafenib—EPHA2—adipose tissue—Graves' disease	0.0027	0.0131	CbGeAlD
Regorafenib—Alopecia—Propylthiouracil—Graves' disease	0.00266	0.0423	CcSEcCtD
Regorafenib—TEK—pituitary gland—Graves' disease	0.00265	0.0128	CbGeAlD
Regorafenib—TEK—adipose tissue—Graves' disease	0.00263	0.0128	CbGeAlD
Regorafenib—FLT1—pituitary gland—Graves' disease	0.00256	0.0124	CbGeAlD
Regorafenib—FLT1—adipose tissue—Graves' disease	0.00255	0.0124	CbGeAlD
Regorafenib—RAF1—pituitary gland—Graves' disease	0.00254	0.0123	CbGeAlD
Regorafenib—RAF1—adipose tissue—Graves' disease	0.00253	0.0123	CbGeAlD
Regorafenib—PDGFRB—eye—Graves' disease	0.00252	0.0122	CbGeAlD
Regorafenib—RET—thyroid gland—Graves' disease	0.0025	0.0121	CbGeAlD
Regorafenib—KIT—connective tissue—Graves' disease	0.00249	0.0121	CbGeAlD
Regorafenib—Thrombocytopenia—Methimazole—Graves' disease	0.00247	0.0392	CcSEcCtD
Regorafenib—PDGFRB—connective tissue—Graves' disease	0.00243	0.0118	CbGeAlD
Regorafenib—PDGFRA—adipose tissue—Graves' disease	0.00239	0.0116	CbGeAlD
Regorafenib—FGFR2—thyroid gland—Graves' disease	0.00238	0.0115	CbGeAlD
Regorafenib—Leukopenia—Propylthiouracil—Graves' disease	0.00235	0.0373	CcSEcCtD
Regorafenib—EPHA2—thyroid gland—Graves' disease	0.00234	0.0113	CbGeAlD
Regorafenib—TEK—thyroid gland—Graves' disease	0.00228	0.0111	CbGeAlD
Regorafenib—ABL1—eye—Graves' disease	0.00225	0.0109	CbGeAlD
Regorafenib—FLT1—thyroid gland—Graves' disease	0.0022	0.0107	CbGeAlD
Regorafenib—RAF1—thyroid gland—Graves' disease	0.00219	0.0106	CbGeAlD
Regorafenib—ABL1—connective tissue—Graves' disease	0.00216	0.0105	CbGeAlD
Regorafenib—KDR—pituitary gland—Graves' disease	0.00216	0.0105	CbGeAlD
Regorafenib—KDR—adipose tissue—Graves' disease	0.00215	0.0104	CbGeAlD
Regorafenib—Thrombocytopenia—Propylthiouracil—Graves' disease	0.0021	0.0333	CcSEcCtD
Regorafenib—PDGFRA—thyroid gland—Graves' disease	0.00207	0.01	CbGeAlD
Regorafenib—Body temperature increased—Methimazole—Graves' disease	0.00199	0.0316	CcSEcCtD
Regorafenib—KIT—pituitary gland—Graves' disease	0.00192	0.00929	CbGeAlD
Regorafenib—KIT—adipose tissue—Graves' disease	0.00191	0.00926	CbGeAlD
Regorafenib—PDGFRB—pituitary gland—Graves' disease	0.00187	0.00908	CbGeAlD
Regorafenib—KDR—thyroid gland—Graves' disease	0.00186	0.00904	CbGeAlD
Regorafenib—PDGFRB—adipose tissue—Graves' disease	0.00186	0.00904	CbGeAlD
Regorafenib—Body temperature increased—Propylthiouracil—Graves' disease	0.00169	0.0269	CcSEcCtD
Regorafenib—ABL1—pituitary gland—Graves' disease	0.00167	0.00809	CbGeAlD
Regorafenib—ABL1—adipose tissue—Graves' disease	0.00166	0.00806	CbGeAlD
Regorafenib—KIT—thyroid gland—Graves' disease	0.00165	0.00801	CbGeAlD
Regorafenib—PDGFRB—thyroid gland—Graves' disease	0.00161	0.00782	CbGeAlD
Regorafenib—Vomiting—Methimazole—Graves' disease	0.0016	0.0254	CcSEcCtD
Regorafenib—Rash—Methimazole—Graves' disease	0.00159	0.0252	CcSEcCtD
Regorafenib—Dermatitis—Methimazole—Graves' disease	0.00159	0.0252	CcSEcCtD
Regorafenib—Headache—Methimazole—Graves' disease	0.00158	0.0251	CcSEcCtD
Regorafenib—Nausea—Methimazole—Graves' disease	0.0015	0.0238	CcSEcCtD
Regorafenib—ABL1—thyroid gland—Graves' disease	0.00144	0.00697	CbGeAlD
Regorafenib—Vomiting—Propylthiouracil—Graves' disease	0.00136	0.0216	CcSEcCtD
Regorafenib—Rash—Propylthiouracil—Graves' disease	0.00135	0.0214	CcSEcCtD
Regorafenib—Dermatitis—Propylthiouracil—Graves' disease	0.00135	0.0214	CcSEcCtD
Regorafenib—Headache—Propylthiouracil—Graves' disease	0.00134	0.0213	CcSEcCtD
Regorafenib—Nausea—Propylthiouracil—Graves' disease	0.00127	0.0202	CcSEcCtD
Regorafenib—CYP2C8—pituitary gland—Graves' disease	0.00108	0.00525	CbGeAlD
Regorafenib—ABCG2—pituitary gland—Graves' disease	0.00105	0.0051	CbGeAlD
Regorafenib—ABCG2—adipose tissue—Graves' disease	0.00105	0.00508	CbGeAlD
Regorafenib—ABCG2—thyroid gland—Graves' disease	0.000907	0.0044	CbGeAlD
Regorafenib—ABCB1—pituitary gland—Graves' disease	0.000519	0.00252	CbGeAlD
Regorafenib—ABCB1—adipose tissue—Graves' disease	0.000517	0.00251	CbGeAlD
Regorafenib—ABCB1—thyroid gland—Graves' disease	0.000447	0.00217	CbGeAlD
Regorafenib—KIT—Innate Immune System—HLA-B—Graves' disease	9.66e-05	0.00105	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—CD8A—Graves' disease	9.64e-05	0.00105	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CTLA4—Graves' disease	9.53e-05	0.00104	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IFIH1—Graves' disease	9.52e-05	0.00104	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IFIH1—Graves' disease	9.5e-05	0.00103	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HLA-B—Graves' disease	9.44e-05	0.00103	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TSHR—Graves' disease	9.42e-05	0.00103	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—IL1B—Graves' disease	9.37e-05	0.00102	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	9.35e-05	0.00102	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HLA-B—Graves' disease	9.27e-05	0.00101	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—HLA-B—Graves' disease	9.16e-05	0.000998	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—CD8A—Graves' disease	9.15e-05	0.000996	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—HLA-B—Graves' disease	9.14e-05	0.000995	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—CD8A—Graves' disease	9.12e-05	0.000993	CbGpPWpGaD
Regorafenib—RAF1—Disease—B3GNT2—Graves' disease	9.04e-05	0.000984	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TSHR—Graves' disease	8.9e-05	0.000969	CbGpPWpGaD
Regorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	8.88e-05	0.000967	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—TSHR—Graves' disease	8.88e-05	0.000966	CbGpPWpGaD
Regorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	8.86e-05	0.000964	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL2RA—Graves' disease	8.85e-05	0.000964	CbGpPWpGaD
Regorafenib—PDGFRB—MAPK Signaling Pathway—TNF—Graves' disease	8.84e-05	0.000963	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-DQB1—Graves' disease	8.8e-05	0.000958	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-B—Graves' disease	8.8e-05	0.000958	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-B—Graves' disease	8.78e-05	0.000956	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-E—Graves' disease	8.75e-05	0.000953	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HLA-A—Graves' disease	8.75e-05	0.000952	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—GC—Graves' disease	8.71e-05	0.000948	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—CXCL10—Graves' disease	8.64e-05	0.000941	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HLA-A—Graves' disease	8.59e-05	0.000935	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IFIH1—Graves' disease	8.56e-05	0.000932	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD40—Graves' disease	8.56e-05	0.000932	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CTLA4—Graves' disease	8.43e-05	0.000918	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—IL2RA—Graves' disease	8.35e-05	0.000909	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IFIH1—Graves' disease	8.34e-05	0.000908	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—HLA-B—Graves' disease	8.23e-05	0.000897	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—CD8A—Graves' disease	8.22e-05	0.000895	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	8.19e-05	0.000892	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-A—Graves' disease	8.15e-05	0.000888	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-A—Graves' disease	8.13e-05	0.000885	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—IFNG—Graves' disease	8.09e-05	0.000881	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-E—Graves' disease	8.04e-05	0.000875	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HLA-B—Graves' disease	8.02e-05	0.000874	CbGpPWpGaD
Regorafenib—EPHA2—Developmental Biology—TNF—Graves' disease	8.01e-05	0.000872	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HLA-DRB1—Graves' disease	7.99e-05	0.00087	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-B—Graves' disease	7.91e-05	0.000861	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	7.9e-05	0.00086	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-E—Graves' disease	7.89e-05	0.000859	CbGpPWpGaD
Regorafenib—RAF1—MAPK Signaling Pathway—TNF—Graves' disease	7.88e-05	0.000858	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD40—Graves' disease	7.85e-05	0.000855	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HLA-DRB1—Graves' disease	7.85e-05	0.000855	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-DQB1—Graves' disease	7.85e-05	0.000854	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—B3GNT2—Graves' disease	7.78e-05	0.000847	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—B3GNT2—Graves' disease	7.78e-05	0.000847	CbGpPWpGaD
Regorafenib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	7.78e-05	0.000847	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CTLA4—Graves' disease	7.74e-05	0.000843	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD40—Graves' disease	7.71e-05	0.00084	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—ICAM1—Graves' disease	7.67e-05	0.000835	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TSHR—Graves' disease	7.65e-05	0.000833	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—IL2RA—Graves' disease	7.64e-05	0.000832	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IFIH1—Graves' disease	7.63e-05	0.00083	CbGpPWpGaD
Regorafenib—KIT—Immune System—CTLA4—Graves' disease	7.6e-05	0.000828	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TSHR—Graves' disease	7.58e-05	0.000825	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—ICAM1—Graves' disease	7.53e-05	0.00082	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-E—Graves' disease	7.49e-05	0.000816	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-E—Graves' disease	7.47e-05	0.000813	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-DRB1—Graves' disease	7.45e-05	0.000811	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-DRB1—Graves' disease	7.43e-05	0.000809	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HLA-B—Graves' disease	7.34e-05	0.000799	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CD8A—Graves' disease	7.33e-05	0.000798	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-A—Graves' disease	7.33e-05	0.000798	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD40—Graves' disease	7.32e-05	0.000797	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD40—Graves' disease	7.3e-05	0.000795	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—IL1B—Graves' disease	7.22e-05	0.000786	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CTLA4—Graves' disease	7.22e-05	0.000786	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CTLA4—Graves' disease	7.2e-05	0.000784	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—ICAM1—Graves' disease	7.15e-05	0.000778	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—ICAM1—Graves' disease	7.13e-05	0.000776	CbGpPWpGaD
Regorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	7.11e-05	0.000774	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-B—Graves' disease	7.05e-05	0.000767	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TSHR—Graves' disease	7.02e-05	0.000765	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-DQB1—Graves' disease	6.94e-05	0.000756	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TSHR—Graves' disease	6.9e-05	0.000751	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—TNF—Graves' disease	6.8e-05	0.00074	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-E—Graves' disease	6.73e-05	0.000733	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-DRB1—Graves' disease	6.69e-05	0.000729	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL2RA—Graves' disease	6.6e-05	0.000719	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—B3GNT2—Graves' disease	6.6e-05	0.000719	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD40—Graves' disease	6.58e-05	0.000716	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-E—Graves' disease	6.56e-05	0.000714	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TSHR—Graves' disease	6.55e-05	0.000713	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TSHR—Graves' disease	6.53e-05	0.000711	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-A—Graves' disease	6.53e-05	0.000711	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CTLA4—Graves' disease	6.48e-05	0.000706	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD8A—Graves' disease	6.48e-05	0.000706	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—ICAM1—Graves' disease	6.42e-05	0.000699	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD40—Graves' disease	6.41e-05	0.000698	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—CD4—Graves' disease	6.39e-05	0.000696	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GC—Graves' disease	6.39e-05	0.000695	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-DQB1—Graves' disease	6.38e-05	0.000694	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CTLA4—Graves' disease	6.32e-05	0.000688	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-DQB1—Graves' disease	6.26e-05	0.000682	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-B—Graves' disease	6.24e-05	0.000679	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CXCL10—Graves' disease	6.08e-05	0.000662	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-E—Graves' disease	6e-05	0.000653	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-DRB1—Graves' disease	5.97e-05	0.00065	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD8A—Graves' disease	5.95e-05	0.000648	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-DQB1—Graves' disease	5.94e-05	0.000647	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-DQB1—Graves' disease	5.93e-05	0.000645	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TSHR—Graves' disease	5.88e-05	0.000641	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—CD4—Graves' disease	5.87e-05	0.000639	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD40—Graves' disease	5.86e-05	0.000638	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD8A—Graves' disease	5.85e-05	0.000637	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL2RA—Graves' disease	5.84e-05	0.000636	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CTLA4—Graves' disease	5.78e-05	0.000629	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-A—Graves' disease	5.78e-05	0.000629	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—CD4—Graves' disease	5.77e-05	0.000628	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CXCL10—Graves' disease	5.75e-05	0.000626	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CXCL10—Graves' disease	5.74e-05	0.000625	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-B—Graves' disease	5.73e-05	0.000623	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—ICAM1—Graves' disease	5.73e-05	0.000623	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—TNF—Graves' disease	5.64e-05	0.000614	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—CD4—Graves' disease	5.64e-05	0.000614	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-B—Graves' disease	5.62e-05	0.000612	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD8A—Graves' disease	5.55e-05	0.000604	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—CD4—Graves' disease	5.54e-05	0.000603	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD8A—Graves' disease	5.53e-05	0.000603	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—CD4—Graves' disease	5.47e-05	0.000596	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—CD4—Graves' disease	5.46e-05	0.000594	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GC—Graves' disease	5.41e-05	0.000589	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL2RA—Graves' disease	5.37e-05	0.000584	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-DQB1—Graves' disease	5.34e-05	0.000581	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-B—Graves' disease	5.34e-05	0.000581	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-B—Graves' disease	5.32e-05	0.00058	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-A—Graves' disease	5.31e-05	0.000578	CbGpPWpGaD
Regorafenib—BRAF—Disease—HLA-A—Graves' disease	5.29e-05	0.000576	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-DRB1—Graves' disease	5.28e-05	0.000575	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL2RA—Graves' disease	5.27e-05	0.000574	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—CD4—Graves' disease	5.25e-05	0.000572	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TSHR—Graves' disease	5.24e-05	0.000571	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—CD4—Graves' disease	5.24e-05	0.000571	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-A—Graves' disease	5.21e-05	0.000567	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-DQB1—Graves' disease	5.2e-05	0.000567	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—ICAM1—Graves' disease	5.07e-05	0.000552	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL2RA—Graves' disease	5e-05	0.000545	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL2RA—Graves' disease	4.99e-05	0.000543	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD8A—Graves' disease	4.99e-05	0.000543	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-A—Graves' disease	4.95e-05	0.000538	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CXCL10—Graves' disease	4.94e-05	0.000538	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-A—Graves' disease	4.93e-05	0.000537	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—CD4—Graves' disease	4.92e-05	0.000535	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HLA-A—Graves' disease	4.9e-05	0.000533	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CXCL10—Graves' disease	4.9e-05	0.000533	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD8A—Graves' disease	4.86e-05	0.000529	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—TNF—Graves' disease	4.85e-05	0.000528	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-DRB1—Graves' disease	4.85e-05	0.000528	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—B3GNT2—Graves' disease	4.84e-05	0.000527	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GC—Graves' disease	4.82e-05	0.000525	CbGpPWpGaD
Regorafenib—KIT—Disease—HLA-A—Graves' disease	4.81e-05	0.000524	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-B—Graves' disease	4.8e-05	0.000522	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—CD4—Graves' disease	4.79e-05	0.000522	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-DRB1—Graves' disease	4.76e-05	0.000518	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-DQB1—Graves' disease	4.76e-05	0.000518	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—CD4—Graves' disease	4.72e-05	0.000514	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GC—Graves' disease	4.71e-05	0.000513	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-B—Graves' disease	4.67e-05	0.000509	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—ICAM1—Graves' disease	4.65e-05	0.000507	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL2RA—Graves' disease	4.65e-05	0.000506	CbGpPWpGaD
Regorafenib—KIT—Immune System—ICAM1—Graves' disease	4.57e-05	0.000498	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HLA-A—Graves' disease	4.57e-05	0.000497	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HLA-A—Graves' disease	4.55e-05	0.000496	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CXCL10—Graves' disease	4.54e-05	0.000494	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-DRB1—Graves' disease	4.52e-05	0.000492	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-DRB1—Graves' disease	4.51e-05	0.000491	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL2RA—Graves' disease	4.49e-05	0.000489	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CXCL10—Graves' disease	4.46e-05	0.000485	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-A—Graves' disease	4.44e-05	0.000484	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD8A—Graves' disease	4.44e-05	0.000484	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GC—Graves' disease	4.4e-05	0.000479	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL2RA—Graves' disease	4.39e-05	0.000478	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL2RA—Graves' disease	4.38e-05	0.000477	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—CD4—Graves' disease	4.38e-05	0.000477	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL2RA—Graves' disease	4.38e-05	0.000477	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—ICAM1—Graves' disease	4.34e-05	0.000472	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-A—Graves' disease	4.33e-05	0.000472	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—ICAM1—Graves' disease	4.33e-05	0.000471	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-B—Graves' disease	4.27e-05	0.000465	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CXCL10—Graves' disease	4.23e-05	0.000461	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CXCL10—Graves' disease	4.22e-05	0.000459	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CD4—Graves' disease	4.21e-05	0.000458	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—TNF—Graves' disease	4.15e-05	0.000452	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HLA-A—Graves' disease	4.1e-05	0.000447	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—B3GNT2—Graves' disease	4.1e-05	0.000446	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-DRB1—Graves' disease	4.06e-05	0.000442	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL2RA—Graves' disease	4.01e-05	0.000436	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-A—Graves' disease	3.96e-05	0.000431	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-DRB1—Graves' disease	3.96e-05	0.000431	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—ICAM1—Graves' disease	3.9e-05	0.000424	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IFNG—Graves' disease	3.86e-05	0.00042	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCL10—Graves' disease	3.8e-05	0.000414	CbGpPWpGaD
Regorafenib—ABL1—Immune System—ICAM1—Graves' disease	3.8e-05	0.000413	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL2RA—Graves' disease	3.78e-05	0.000411	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL2RA—Graves' disease	3.74e-05	0.000408	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD4—Graves' disease	3.72e-05	0.000405	CbGpPWpGaD
Regorafenib—RAF1—Disease—HLA-A—Graves' disease	3.66e-05	0.000398	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—B3GNT2—Graves' disease	3.66e-05	0.000398	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—TNF—Graves' disease	3.64e-05	0.000396	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-DRB1—Graves' disease	3.62e-05	0.000394	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—B3GNT2—Graves' disease	3.57e-05	0.000389	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IFNG—Graves' disease	3.54e-05	0.000385	CbGpPWpGaD
Regorafenib—KIT—Immune System—IFNG—Graves' disease	3.48e-05	0.000379	CbGpPWpGaD
Regorafenib—RAF1—Immune System—ICAM1—Graves' disease	3.47e-05	0.000378	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL2RA—Graves' disease	3.47e-05	0.000378	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL1B—Graves' disease	3.44e-05	0.000374	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD4—Graves' disease	3.42e-05	0.000372	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL2RA—Graves' disease	3.41e-05	0.000371	CbGpPWpGaD
Regorafenib—BRAF—Disease—CD4—Graves' disease	3.41e-05	0.000371	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL10—Graves' disease	3.39e-05	0.000369	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD4—Graves' disease	3.36e-05	0.000366	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	3.35e-05	0.000365	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—B3GNT2—Graves' disease	3.33e-05	0.000363	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TNF—Graves' disease	3.33e-05	0.000362	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IFNG—Graves' disease	3.3e-05	0.000359	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IFNG—Graves' disease	3.29e-05	0.000358	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL2RA—Graves' disease	3.23e-05	0.000352	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL2RA—Graves' disease	3.23e-05	0.000351	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD4—Graves' disease	3.19e-05	0.000347	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD4—Graves' disease	3.18e-05	0.000346	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL1B—Graves' disease	3.16e-05	0.000344	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CD4—Graves' disease	3.16e-05	0.000344	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL1B—Graves' disease	3.1e-05	0.000338	CbGpPWpGaD
Regorafenib—KIT—Disease—CD4—Graves' disease	3.1e-05	0.000338	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IFNG—Graves' disease	2.97e-05	0.000323	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1B—Graves' disease	2.94e-05	0.00032	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CD4—Graves' disease	2.94e-05	0.00032	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1B—Graves' disease	2.94e-05	0.00032	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CD4—Graves' disease	2.93e-05	0.00032	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2RA—Graves' disease	2.91e-05	0.000316	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GC—Graves' disease	2.9e-05	0.000316	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IFNG—Graves' disease	2.89e-05	0.000315	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD4—Graves' disease	2.86e-05	0.000312	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD4—Graves' disease	2.79e-05	0.000304	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1B—Graves' disease	2.64e-05	0.000288	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CD4—Graves' disease	2.64e-05	0.000288	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IFNG—Graves' disease	2.64e-05	0.000288	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2RA—Graves' disease	2.59e-05	0.000282	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1B—Graves' disease	2.58e-05	0.000281	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD4—Graves' disease	2.55e-05	0.000278	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1B—Graves' disease	2.36e-05	0.000257	CbGpPWpGaD
Regorafenib—RAF1—Disease—CD4—Graves' disease	2.36e-05	0.000257	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—B3GNT2—Graves' disease	2.2e-05	0.000239	CbGpPWpGaD
